Discovery of inhibitors of 4'-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6005-6015

  De Jonge, Boudewijn L M ^a   Walkup, Grant K ^a   Lahiri, Sushmita D ^a   Huynh, Hoan ^a   Neckermann, Georg ^a   Utley, Luke ^a,b   Nash, Tory J ^a   Brock, Jesse ^a   San Martin, Maryann ^a   Kutschke, Amy ^a   Johnstone, Michele ^a   Laganas, Valerie ^a   Hajec, Laurel ^a   Gu, Rong Fang ^a   Ni, Haihong ^a,c   Chen, Brendan ^a   Hutchings, Kim ^a,d   Holt, Elise ^a   McKinney, David ^a   Gao, Ning ^a   Livchak, Stephania ^a   Thresher, Jason ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b AGIOS PHARMACEUTICALS   (United States)

^c BioDuro   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE; 4' PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE INHIBITOR; ANTIBIOTIC AGENT; BACTERIAL ENZYME; ISOENZYME; LINEZOLID; PANTETHEINE PHOSPHATE; PYRIMIDINE DERIVATIVE; PYRROLAMIDE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; 4'-PHOSPHOPANTETHEINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; ENZYME INHIBITOR; MOLECULAR LIBRARY; NUCLEOTIDYLTRANSFERASE; PANTETHEINE; PANTETHEINE-PHOSPHATE ADENYLYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIUM MUTANT; BINDING COMPETITION; BONE INFECTION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DATABASE; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; ENZYME INHIBITION; FEMALE; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; THIGH; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; LUNG; METABOLISM; MICROBIOLOGY; MOLECULAR LIBRARY; PHARMACOLOGY; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BINDING, COMPETITIVE; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME INHIBITORS; FEMALE; LUNG; MICE; MODELS, MOLECULAR; NUCLEOTIDYLTRANSFERASES; PANTETHEINE; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL; SMALL MOLECULE LIBRARIES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THIGH;

EID: 84887500551     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01661-13     Document Type: Article

References (45)

1. Fauci AS, Morens DM. 2012. The perpetual challenge of infectious diseases. N. Engl. J. Med. 366:454-461.
2. Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. 2009. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. 49:1175-1184.
3. Arias CA, Murray BE. 2009. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N. Engl. J. Med. 360:439-443.
4. Nordmann P, Poirel L, Toleman MA, Walsh TR. 2011. Does broadspectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother. 66:689-692.
5. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJV, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9:894-896.
6. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10:S122-S129.
7. Silver LL. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24:71-109.
8. Payne DJ, Gwynn MN, Holmes DJ, Pompliano D. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
9. Barrett JF. 2006. Impact of genomics-emerging targets for antibacterial therapy. Comp. Med. Chem. II 7:731-748.
10. Miller JR, Thanabal V, Melnick MM, Lall M, Donovan C, Sarver RW, Lee D-Y, Ohren J, Emerson D. 2010. The use of biochemical and biophysical tools for triage of high-throughput screening hits-a case study with Escherichia coli phosphopantetheine adenylyltransferase. Chem. Biol. Drug Des. 75:444-454.
11. Zhao L, Allanson NM, Thomson SP, Maclean JKF, Barker JJ, Primrose WU, Tyler PD, Lewendon A. 2003. Inhibitors of phosphopantetheine adenylyltransferase. Eur. J. Med. Chem. 38:345-349.
12. Zhang YM, White SW, Rock CO. 2006. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem. 281:17541-17544.
13. Spry C, Kirk K, Saliba KJ. 2008. Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiol. Rev. 32:56-106.
14. Leonardi R, Zhang Y-M, Rock CO, Jackowski S. 2005. Coenzyme A: back in action. Progr. Lipid Res. 44:125-153.
15. Izard T, Geerlof A. 1999. The crystal structure of a novel bacterial adenylyltransferase reveals half of sites reactivity. EMBO J. 18:2021-2030.
16. Geerlof A, Lewendon A, Shaw WV. 1999. Purification and characterization of phosphopantetheine adenylyltransferase from Escherichia coli. J. Biol. Chem. 274:27105-27111.
17. Freiberg C, Wieland B, Spaltmann F, Ehlert K, Brötz H, Labischinski H. 2001. Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria. J. Mol. Microbiol. Biotechnol. 3:483-489.
18. Gerdes SY, Scholle MD, D'Souza M, Bernal A, Baev MV, Farrell M, Kurnasov OV, Daugherty MD, Mseeh F, Polanuyer BM, Campbell JW, Anantha S, Shatalin KY, Chowdhury SAK, Fonstein MY, Osterman AL. 2002. From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. 184:4555-4572.
19. Daugherty M, Polanuyer B, Farrell M, Scholle M, Lykidis A, de Crecy-Lagard V, Osterman A. 2002. Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. J. Biol. Chem. 277:21431-21439.
20. Genschel U. 2004. Coenzyme A biosynthesis: reconstruction of the pathway in archaea and an evolutionary scenario based on comparative genomics. Mol. Biol. Evol. 21:1242-1251.
21. Mandel AL, La Clair JJ, Burkart MD. 2004. Modular synthesis of pantetheine and phosphopantetheine. Org. Lett. 6:4801-4803.
22. Mills SD, Eakin AE, Buurman ET, Newman JV, Gao N, Huynh H, Johnson KD, Lahiri S, Shapiro AB, Walkup GK, Yang W, Stokes SS. 2011. Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo. Antimicrob. Agents Chemother. 55:1088-1096.
23. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. M07-A8, vol 29, no. 2. Clinical and Laboratory Standards Institute, Wayne, PA.
24. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. M26-A, vol 19, no. 18. National Committee for Clinical Laboratory Standards, Wayne, PA.
25. Tomasz A, Moreillon P, Pozzi G. 1988. Insertional inactivation of the major autolysin gene of Streptococcus pneumoniae. J. Bacteriol. 170:5931-5934.
26. Yang J, Copeland RA, Lai Z. 2009. Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. J. Bimol. Screen. 14:111-120.
27. Shapiro AB, Gao N, Thresher J, Walkup GK, Whiteaker J. 2011. A high-throughput absorbance-based assay for methionine produced by methionine aminopeptidase using S-adenosyl-L-methionine synthetase. J. Biomol. Screen. 16:494-505.
28. Keating TA, Newman JV, Olivier NB, Otterson LG, Andrews B, Boriack-Sjodin PA, Breen JN, Doig P, Dumas J, Gangl E, Green OM, Guler SY, Hentemann MF, Joseph-McCarthy D, Kawatkar S, Kutschke A, Loch JT, McKenzie AR, Pradeepan S, Prasad S, Martínez-Botella G. 2012. In vivo validation of thymidylate kinase (TMK) with a rationally-designed, selective antibacterial compound. ACS Chem. Biol. 7:1866-1872.
29. Jancarik J, Kim SH. 1991. Sparse matrix sampling: a screening method for crystallization of proteins. J. Appl. Crystallogr. 24:409-411.
30. Smart OS, Womack TO, Flensburg C, Keller P, Paciorek W, Sharff A, Vonrhein C, Bricogne G. 2012. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D Biol. Crystallogr. 68(Pt 4):368-380.
31. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60(Pt 12 Pt 1):2126-2132.
32. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. 1993. PROCHECK-a program to check the stereochemical quality of protein structures. J. App. Cryst. 26:283-291.
33. Balani SK, Li P, Nguyen J, Cardoza K, Zeng H, Mu D-X, Wu J-T, Gan L-S, Lee FW. 2004. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab. Dispos. 32:1092-1095.
34. Azoulay-Dupuis E, Bedos JP, Vallée E, Hardy DJ, Swanson RN, Pocidalo JJ. 1991. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J. Infect. Dis. 163:319-324.
35. Sherer BA, Hull K, Green O, Basarab G, Hauck S, Hill P, Loch JT, Mullen G, Bist S, Bryant J, Boriack-Sjodin A, Read J, DeGrace N, Uria-Nickelsen M, Illingworth RN, Eakin AE. 2011. Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy. Bioorg. Med. Chem. Lett. 21:7416-7420.
36. Yoon HJ, Kang JY, Mikami B, Lee HH, Suh SW. 2011. Crystal structure of phosphopantetheine adenylyltransferase from Enterococcus faecalis in the ligand-unbound state and in complex with ATP and pantetheine. Mol. Cells 32:431-435.
37. Leskovac V. 2003. Comprehensive enzyme kinetics. Kluwer Academic Press, Boston, MA.
38. Izard T. 2002. The crystal structures of phosphopantetheine adenylyltransferase with bound substrates reveal the enzyme's catalytic mechanism. J. Mol. Biol. 315:487-495.
39. Miller JR, Ohren J, Sarver RW, Mueller WT, de Dreu P, Case H, Thanabal V. 2007. Phosphopantetheine adenylyltransferase from Escherichia coli: investigation of the kinetic mechanism and role in regulation of coenzyme A biosynthesis. J. Bacteriol. 189:8196-8205.
40. Segel IH. 1975. Enzyme kinetics. Wiley-Interscience, New York, NY.
41. Korycka-Machala M, Rychta E, Brzostek A, Sayer HR, Rumijowska-Galewicz A, Bowater RP, Dziadek J. 2007. Evaluation of NAD+-dependentDNAligase of mycobacteria as a potential target for antibiotics. Antimicrob. Agents Chemother. 51:2888-2897.
42. Kumar A, Schweizer HP. 2005. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv. Drug Deliv. Rev. 57:1486-1513.
43. Seydel JK, Wempe E, Miller GH, Miller L. 1973. Quantification of the antibacterial action of trimethoprim alone and in combination with sulfonamides by bacterial growth kinetics. J. Infect. Dis. 128(Suppl): 463-469.
44. Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ. 2004. The importance of bactericidal drugs: future directions in infectious disease. Clin. Infect. Dis. 39:1314-1320.
45. Blondeau JM. 2009. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet. Dermatol. 20:383-396.